The Advanced Medical Technology Association (AdvaMed) has voiced its support for the White House’s “America’s AI Action Plan.”

In a public statement, AdvaMed President and CEO Scott Whitaker expressed eagerness to collaborate on future artificial intelligence (AI)-driven health care initiatives to improve health care delivery and patient outcomes. 

According to AdvaMed, recent AI advancements have enabled earlier, faster, and more accurate diagnoses, reduced need for unnecessary procedures, and lower health care system costs. As an example in the statement, Mr. Whitaker cited a recent study that demonstrated a 29% increase in early breast cancer detection using AI technology.

The US Food and Drug Administration (FDA) has updated its list of authorized AI-enabled products, which now number more than 1200. These devices span a wide range of clinical applications, from pathology and ophthalmology to diagnostics.

This increase reflects growing adoption of AI across the medtech sector in both consumer-facing and clinical systems.

In addition to alignment with the White House’s vision of AI use, AdvaMed has also released its own AI Policy Roadmap, which outlines strategies to ensure responsible deployment of AI in health care; promote transparency, safety, and effectiveness in AI-enabled devices; and streamline regulatory pathways for AI product approval.

Mr. Whitaker noted that AdvaMed will work closely with federal agencies to ensure policies foster innovation while protecting patient safety.